O.A.vdH.: Lecture honorarium Benecke. II: Data safety monitoring committee Lundbeck. H.B.S.: Research Support from Biohaven Pharmaceuticals for mutisite industry‐sponsored clinical trial, royalties from UpToDate Inc and Cambridge University Press, stipend from the American Medical Association for servicing as Associate Editor of JAMA Psychiatry. N.J.: MPI of a research related grant from Biogen Inc, for work unrelated to the contents of this manuscript. J.K.B.: has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Shire, Roche, Medice, and Servier—he is not an employee of any of these companies, and not a stock shareholder of any of these companies—he has no other financial or material support, including expert testimony, patents, royalties. B.P.B.: Research support from Eli Lilly, Transcept Pharamaceuticals, and Biohaven Pharmaceuticals. Consulting fees from Rugen Therapeutics and Nobilis Therapeutics. D.M.C.: royalties for contributing articles to UpToDate, Wolters Kluwer Health, and for editorial work from Elsevier. P.M.: CME‐related honoraria, or consulting fees from Angelini, AstraZeneca, Bial Foundation, Biogen, DGS‐Portugal, Janssen‐Cilag, Springer Healthcare and 2CA‐Braga. E.N.: Medical/Scientific Advisory Boards: Teva Pharmaceuticals, Myriad Genetics. C.P.: Research support from
